Assertio (ASRT) Expected to Announce Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT) is projected to issue its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $27.02 million for the quarter. Assertio has set its FY 2025 guidance at EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Assertio (NASDAQ:ASRT) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Assertio had a negative return on equity of 38.19% and a negative net margin of 36.97%.The firm had revenue of $29.22 million during the quarter, compared to analysts’ expectations of $27.86 million. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Assertio Stock Performance

Shares of NASDAQ ASRT opened at $0.74 on Monday. The stock has a market cap of $71.64 million, a price-to-earnings ratio of -1.65 and a beta of 0.28. Assertio has a 12 month low of $0.51 and a 12 month high of $1.08. The company has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $0.74. The company has a current ratio of 1.59, a quick ratio of 1.34 and a debt-to-equity ratio of 0.42.

Institutional Investors Weigh In On Assertio

A hedge fund recently raised its stake in Assertio stock. Nantahala Capital Management LLC boosted its position in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 4.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,810,073 shares of the company’s stock after buying an additional 370,311 shares during the period. Nantahala Capital Management LLC owned 9.15% of Assertio worth $5,649,000 at the end of the most recent quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ASRT. HC Wainwright lowered their price target on shares of Assertio from $3.50 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Assertio in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded Assertio from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $2.38.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.